GlassScriptPhysician profile
John D Christein
NPI 1508809328
$2,076.84
in general payments reported to CMS, 2019-2025
25 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $66.23 · 2021: $303 · 2022: $284 · 2023: $425 · 2024: $409 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Consulting Fee: $142 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.84 |
| Consulting Fee | $141.67 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $437.68 | 2019-2025 | Axios |
| Angiodynamics, INC. | $362.53 | 2022-2025 | Nanoknife |
| Baxter Healthcare | $263.12 | 2021-2022 | |
| Octapharma USA, INC. | $179.12 | 2022-2025 | Octagam Immune Globulin (Human) |
| Zoll Medical Corporation | $141.67 | 2023 | |
| Janssen Biotech, INC. | $90.26 | 2019-2024 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $83.93 | 2022-2025 | Imfinzi |
| Pharmacyclics LLC, An Abbvie Company | $67.16 | 2021-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $62.36 | 2023-2024 | |
| Daiichi Sankyo INC. | $55.39 | 2024 | Enhertu |
| Ethicon US, LLC | $34.68 | 2025 | Vistaseal |
| Taiho Oncology, INC. | $29.10 | 2020-2022 | |
| Seagen INC. | $28.63 | 2020-2021 | |
| Tela Bio, INC. | $28.47 | 2022 | |
| Merck Sharp & Dohme LLC | $27.12 | 2023 | Keytruda |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.57 | 2025 | Xtandi |
| Eisai INC. | $22.64 | 2019 | |
| Pharmacosmos Therapeutics INC. | $22.34 | 2025 | Monoferric |
| Genentech USA, INC. | $19.82 | 2025 | Polivy |
| Puma Biotechnology, INC. | $18.23 | 2021 | |
| Abbvie INC. | $17.13 | 2025 | |
| Incyte Corporation | $17.12 | 2020 | |
| Karyopharm Therapeutics INC. | $16.66 | 2021 | |
| Pfizer INC. | $13.78 | 2022 | |
| Array Biopharma INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Christein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.